Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

This trial (BELIEVE-VHL) is studying the real-world effectiveness of belzutifan — an oral drug — in people with von Hippel-Lindau (VHL) syndrome, a rare genetic condition that causes tumors to grow in the kidneys, brain, eyes, and other organs. The study also looks at whether genetic variations affect how patients respond to belzutifan. **You may be eligible if...** - You are 14 years or older - You have a confirmed diagnosis of VHL syndrome (by genetic testing or clinical criteria) - You have measurable or growing tumors related to VHL - You are in reasonable overall health - You can swallow oral medication **You may NOT be eligible if...** - You are under 14 years old - Your VHL diagnosis has not been confirmed - You have had another unrelated cancer within the past 3 years (some skin cancers excepted) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.